{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"0.000"},{"groupId":"OG001","spread":"0.0000","value":"0.000"},{"groupId":"OG002","spread":"0.0000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.4678","value":"92.757"},{"groupId":"OG001","spread":"35.0687","value":"83.566"},{"groupId":"OG002","spread":"16.3712","value":"106.944"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.5832","value":"187.171"},{"groupId":"OG001","spread":"72.2766","value":"181.600"},{"groupId":"OG002","spread":"80.4607","value":"223.956"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 15, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"271.6850","value":"306.243"},{"groupId":"OG001","spread":"94.5186","value":"238.788"},{"groupId":"OG002","spread":"87.6985","value":"305.444"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"143.1613","value":"297.850"},{"groupId":"OG001","spread":"206.5359","value":"235.865"},{"groupId":"OG002","spread":"182.0090","value":"346.957"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"180.6967","value":"368.400"},{"groupId":"OG001","spread":"158.6950","value":"267.740"},{"groupId":"OG002","spread":"104.3532","value":"260.250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 2 DAY 15, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"258.3001","value":"478.250"},{"groupId":"OG001","spread":"195.5971","value":"249.040"},{"groupId":"OG002","spread":"144.9341","value":"388.500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"CYCLE 3 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"158.3759","value":"423.250"},{"groupId":"OG001","spread":"49.4975","value":"309.000"},{"groupId":"OG002","spread":"197.7291","value":"413.600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"CYCLE 3 DAY 15, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"471.7121","value":"555.333"},{"groupId":"OG001","spread":"216.9686","value":"162.580"},{"groupId":"OG002","spread":"108.4706","value":"460.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"337.5001","value":"459.333"},{"groupId":"OG001","spread":"219.3445","value":"179.900"},{"groupId":"OG002","spread":"115.0795","value":"446.600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"CYCLE 4 DAY 15, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"224.0855","value":"403.333"},{"groupId":"OG001","spread":"216.7989","value":"171.700"},{"groupId":"OG002","spread":"136.8843","value":"440.400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"CYCLE 5 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"228.0592","value":"351.000"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"420.000"},{"groupId":"OG002","spread":"45.1101","value":"468.750"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 6 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"649.000"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"304.000"},{"groupId":"OG002","spread":"54.9121","value":"503.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 7 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"665.000"},{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG001","spread":"NA","value":"121.000"},{"groupId":"OG002","spread":"87.2788","value":"447.250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"CYCLE 8 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"113.1371","value":"493.000"},{"groupId":"OG002","spread":"114.5513","value":"449.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"CYCLE 9 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"comment":"SD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.","groupId":"OG000","spread":"NA","value":"413.000"},{"groupId":"OG002","spread":"114.5513","value":"458.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"CYCLE 10 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"212.0699","value":"289.490"},{"groupId":"OG001","spread":"200.3017","value":"202.613"},{"groupId":"OG002","spread":"202.2553","value":"276.717"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"END OF TREATMENT (~194 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of Isatuximab when administered intravenously in combination with belantamab mafodotin.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin end of infusion (EOI), administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W), and thereafter on day 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab"},{"description":"Participants with RRMM received 1.4 mg/kg of belantamab mafodotin IV infusion, once every 8 weeks (Q8W) infused over 30- 60 minutes on day 1 of each 56 day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin EOI administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W) and thereafter on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG001","title":"1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab"},{"description":"Participants with RRMM received 1.9 mg/kg of belantamab mafodotin IV infusion, Q8W infused over 30- 60 minutes on day 1 of each 56 day cycle in combination with 10 mg/kg isatuximab, given 1 hour after belantamab mafodotin EOI administered as an IV infusion once weekly (Q1W) for 5 doses, then every 2 weeks (Q2W) and thereafter on days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG002","title":"1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab"}],"paramType":"MEAN","populationDescription":"PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The \"0\" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.","reportingStatus":"POSTED","timeFrame":"Predose on Cycle (C)1 Day (D)1, D8, D15 and D22; predose on C2D1 and C2D15; predose on C3D1 and C3D15; predose on C4D1 and C4D15; predose on C5D1, C6D1, C7D1, C8D1, C9D1 and C10D1; and end of treatment (~194 weeks).","title":"DE Phase: Isatuximab Concentration When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}